HBY 946

Drug Profile

HBY 946

Alternative Names: BAY-946; HBY-946; HOE-946; HOE-BAY-946; Hoe/Bay 946

Latest Information Update: 09 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis; Bayer
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 24 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
  • 24 Nov 1997 Phase-II clinical trials for HIV infections treatment (Unknown route)
  • 10 Jan 1997 Investigation in HIV infections treatment (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top